🧪 UPDATED DAILY FROM CLINICALTRIALS.GOVSynced today

Find Clinical Trials for Your Rare Disease

12074+ recruiting trials across all rare diseases. Filter by phase, location, and condition.

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Showing 20 of 12074 recruiting trials

NARecruitingNCT06150742

Nafamostat Efficacy in Phase 3 Registrational CRRT Study

🏥 Talphera, Inc📍 10 sites📅 Started Aug 2024View details ↗
NARecruitingNCT06241274

Moxibustion in the Treatment of Hemorrhagic Cystitis After Allo-HSCT

🏥 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology📍 1 site📅 Started Aug 2024View details ↗
NARecruitingNCT06495554

Danish Vulva Cancer Recurrence Study

👨‍⚕️ Pernille T. Jensen, Professor, Aarhus University Hospital📍 2 sites📅 Started Aug 2024View details ↗
Phase 1, PHASE2RecruitingNCT06546670

A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease

🏥 Novartis Pharmaceuticals📍 3 sites📅 Started Aug 2024View details ↗
NARecruitingNCT06539026

Inferior Vena Cava Collapsibility Index Guide for Preoperative Fluid Therapy in Preeclampsia

🏥 Ain Shams University📍 1 site📅 Started Aug 2024View details ↗
RecruitingNCT06561399

Triple Therapy Sequential Radiotherapy in Unresectable HCC (TALENP003)

👨‍⚕️ Shao-Ming Wei, Fujian Provincial Hospital📍 4 sites📅 Started Aug 2024View details ↗
Phase 2RecruitingNCT06554626

Blinatumomab Plus Venetoclax Sequenced With Inotuzumab Ozogamicin in Treating B-ALL

🏥 First Affiliated Hospital of Zhejiang University📍 1 site📅 Started Aug 2024View details ↗
Phase 1RecruitingNCT06399640

Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia

👨‍⚕️ Somedeb Ball, MD, Vanderbilt University/Ingram Cancer Center📍 1 site📅 Started Aug 2024View details ↗
RecruitingNCT06547099

Study to Understand Novel Biomarkers in Researching Dementia

👨‍⚕️ Randall Bateman, MD, Washington University School of Medicine📍 1 site📅 Started Aug 2024View details ↗
Phase 1RecruitingNCT06308419

A Phase I Trial of Combination Gemcitabine and Nab-Sirolimus in Advanced Leiomyosarcomas or Advanced Soft-Tissue Sarcomas With TSC2 or TSC1 Loss-of-function Mutations or Deletions

👨‍⚕️ Elise Nassif, MD, M.D. Anderson Cancer Center📍 1 site📅 Started Aug 2024View details ↗
Phase 1RecruitingNCT05687123

Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors

👨‍⚕️ Nikolaos Trikalinos, Yale University Cancer Center LAO📍 10 sites📅 Started Aug 2024View details ↗
Phase 2RecruitingNCT06467617

Adebrelimab Plus Chemo and Recaticimab in Perioperative Treatment of Resectable NSCLC

👨‍⚕️ Jinghui Wang, Director of Research Laboratory, Beijing Chest Hospital📍 1 site📅 Started Aug 2024View details ↗
Phase 3RecruitingNCT06435429

A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer

🏥 Jazz Pharmaceuticals📍 166 sites📅 Started Aug 2024View details ↗
RecruitingNCT06861530

A Swiss Assessment of Hypothalamic-pituitary-adrenal Axis Suppression After Glucocorticoid Therapy for Leukemia and Lymphoblastic Lymphoma in Children

🏥 University Children's Hospital Basel📍 2 sites📅 Started Aug 2024View details ↗
Phase 2RecruitingNCT06580574

Immune Checkpoint Inhibitors for Organ Preservation in Non-metastatic dMMR/MSI-H Gastric or Colon Cancers

👨‍⚕️ Lin Shen, Peking University Cancer Hospital & Institute📍 1 site📅 Started Aug 2024View details ↗
Phase 2RecruitingNCT06353906

Carboplatin/Paclitaxel + Pembrolizumab for Locoregionally Advanced Penile Cancer

👨‍⚕️ Michiel S. van der Heijden, PhD, The Netherlands Cancer Institute📍 2 sites📅 Started Aug 2024View details ↗
Phase 1, PHASE2RecruitingNCT04173650

MSC EVs in Dystrophic Epidermolysis Bullosa

👨‍⚕️ David T Woodley, MD, University of Southern California Dept of Dermatology📍 3 sites📅 Started Aug 2024View details ↗
NARecruitingNCT06529250

Intermediate-dose HAD Regimen for CEBPA Double-mutated AML

👨‍⚕️ Hui Wei, MD, Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College📍 1 site📅 Started Aug 2024View details ↗
Phase 3RecruitingNCT06545526

Chemopreventive Effect of Combination of Celecoxib and Metformin in Patients With Familial Adenomatous Polyposis

🏥 Yonsei University📍 1 site📅 Started Aug 2024View details ↗
Phase 1, PHASE2RecruitingNCT06592170

Linperlisib Combination With Obinutuzumab Frontline Treatment of Marginal Zone Lymphoma Patients (MZL)

🏥 The First Hospital of Jilin University📍 1 site📅 Started Aug 2024View details ↗
← PreviousPage 254 of 604Next →

Get alerts when new trials open

Create a free account to follow conditions and receive trial notifications.

Create free account →